Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
BTIG analyst Julian Harrison maintains $Aclaris Therapeutics(ACRS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 52.7% and a total average return of 15.8% over
Aclaris Therapeutics' ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
Express News | Aclaris Therapeutics Inc - Topline Data Expected in First Half of 2025
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Express News | Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent Itk/Jak3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Seborrheic Keratosis Treatment Market Report 2024-2030, Featuring Comprehensive Profiles of Aclaris Therapeutics, Alma Lasers, BIOLASE, BioLineRx, DermBiont, Novartis and Pulse Biosciences
H.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Aclaris Therapeutics | 10-Q: Q2 2024 Earnings Report
Aclaris' Cash, Cash Equivalents And Marketable Securities Of $149.9M As Of June 30, 2024 And $26.5M From Sale Of Olumiant Royalties And Milestones Will Be Sufficient To Fund Its Operations Into 2028
Express News | Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Express News | Aclaris Therapeutics Q2 Revenue USD 2.766 Million
Express News | Aclaris Therapeutics Q2 Net Income USD -10.986 Million
Press Release: Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics 2Q Rev $2.77M >ACRS
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?